265 related articles for article (PubMed ID: 28391613)
41. [Two cases of RA-like and SLE-like features similar to remitting seronegative symmetrical synovitis with pitting edema (RS3PE syndrome)].
Yamanishi Y; Taooka Y; Mukuzono H; Aoi K; Ishibe Y; Yamana S
Ryumachi; 1993 Apr; 33(2):162-8. PubMed ID: 8316907
[TBL] [Abstract][Full Text] [Related]
42. Nivolumab therapy before vemurafenib administration induces a severe skin rash.
Imafuku K; Yoshino K; Ymaguchi K; Tsuboi S; Ohara K; Hata H
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):e169-e171. PubMed ID: 27546003
[No Abstract] [Full Text] [Related]
43. Nivolumab for adjuvant treatment of desmoplastic malignant melanoma: A case report.
Shibata T; Iwashita N; Takama H; Yanagishita T; Takeo T; Oshima Y; Watanabe D; Tsuzuki T
J Dermatol; 2020 Jan; 47(1):e6-e7. PubMed ID: 31701575
[No Abstract] [Full Text] [Related]
44. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
[TBL] [Abstract][Full Text] [Related]
45. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
[No Abstract] [Full Text] [Related]
46. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
[No Abstract] [Full Text] [Related]
47. Acute Onset of Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Two Weeks After COVID-19 Vaccination With mRNA-1273 With Possible Activation of Parvovirus B19: A Case Report With Literature Review.
Arino H; Muramae N; Okano M; Mori K; Otsui K; Sakaguchi K
Cureus; 2022 May; 14(5):e24952. PubMed ID: 35706724
[TBL] [Abstract][Full Text] [Related]
48. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
Alnabulsi R; Hussain A; DeAngelis D
Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
[TBL] [Abstract][Full Text] [Related]
49. Clinical outcomes in the first year of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome.
Origuchi T; Arima K; Umeda M; Kawashiri SY; Tamai M; Nakamura H; Tsukada T; Miyashita T; Iwanaga N; Izumi Y; Furuyama M; Tanaka F; Kawabe Y; Aramaki T; Ueki Y; Eguchi K; Fukuda T; Kawakami A
Mod Rheumatol; 2017 Jan; 27(1):150-154. PubMed ID: 27320419
[TBL] [Abstract][Full Text] [Related]
50. Remitting, seronegative (A) symmetrical synovitis with pitting edema--two cases of RS3PE syndrome.
Pariser KM; Canoso JJ
J Rheumatol; 1991 Aug; 18(8):1260-2. PubMed ID: 1941838
[TBL] [Abstract][Full Text] [Related]
51. Clinical analysis of pre-existing diabetes mellitus and dipeptidyl peptidase-4 inhibitors in patients with remitting seronegative symmetrical synovitis and pitting edema syndrome.
Horai Y; Origuchi T; Iwanaga N; Tokumitsu J; Ikeoka T; Kuriya G; Izumi Y; Kawakami A
Mod Rheumatol; 2020 Jul; 30(4):703-707. PubMed ID: 31500483
[No Abstract] [Full Text] [Related]
52. Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report.
Antoniou S; Bazazo G; Röckl L; Papadakis M; Berg C
BMC Endocr Disord; 2021 Sep; 21(1):191. PubMed ID: 34544399
[TBL] [Abstract][Full Text] [Related]
53. Unique and distinctive histological features of immunotherapy-related thyroiditis.
Zaborowski M; Sywak M; Nylén C; Gill AJ; Chou A
Pathology; 2020 Feb; 52(2):271-273. PubMed ID: 31902621
[No Abstract] [Full Text] [Related]
54. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report.
Yonezaki K; Kobayashi T; Imachi H; Yoshimoto T; Kikuchi F; Fukunaga K; Sato S; Ibata T; Yamaji N; Lyu J; Dong T; Murao K
J Med Case Rep; 2018 Jun; 12(1):171. PubMed ID: 29914537
[TBL] [Abstract][Full Text] [Related]
55. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome accompanied by Parkinson's disease.
Ito E; Okamoto H; Mochizuki A; Ohara K; Kato M; Terashima Y; Tanaka E; Takagi K; Uchiyama S; Iwata M
Intern Med; 2007; 46(14):1139-42. PubMed ID: 17634716
[TBL] [Abstract][Full Text] [Related]
56. An update on the safety of nivolumab for the treatment of advanced melanoma.
Czarnecka AM; Rutkowski P
Expert Opin Drug Saf; 2020 Apr; 19(4):409-421. PubMed ID: 32293935
[No Abstract] [Full Text] [Related]
57. Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient.
Chersi F; Conforti C; Zalaudek I; Bazzacco G; Zelin E; di Meo N
Melanoma Res; 2023 Jun; 33(3):262-263. PubMed ID: 37114722
[No Abstract] [Full Text] [Related]
58. [The remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome].
Bonapart IE; van Paassen HC; Wouters JM
Ned Tijdschr Geneeskd; 1996 Jul; 140(29):1512-4. PubMed ID: 8765938
[TBL] [Abstract][Full Text] [Related]
59. A Rare Side Effect of Checkpoint Inhibitor Therapy-Nivolumab-Induced Axial Polyarthritis of the Facet and Costovertebral Joints.
Feist J; Murray A; Skapenko A; Schulze-Koops H
Arthritis Rheumatol; 2019 Nov; 71(11):1823. PubMed ID: 31297971
[No Abstract] [Full Text] [Related]
60. Fatal myasthenia gravis (MG) associated with myositis and myocarditis in a patient with pre-existing MG treated by adjuvant nivolumab for a stage III melanoma.
Emile J; Cauquil C; Carpentier D; Routier E; Robert C
Eur J Cancer; 2024 Jul; 205():114098. PubMed ID: 38761774
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
